Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
about
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisA cytokine-centric view of the pathogenesis and treatment of autoimmune arthritisDry eye: an inflammatory ocular diseaseJakpot! New small molecules in autoimmune and inflammatory diseasesPathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementA Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint InflammationTyrosine kinase inhibitors for the treatment of rheumatoid arthritisTofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studiesApplication of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in JapaneseImproved efficacy of allergen-specific immunotherapy by JAK inhibition in a murine model of allergic asthma.Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunctionModel-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.Update on Janus kinase antagonists in inflammatory bowel disease.Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).An N-ethyl-N-nitrosourea (ENU)-induced dominant negative mutation in the JAK3 kinase protects against cerebral malariaTofacitinib for the treatment of rheumatoid arthritis.JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy.Oclacitinib (APOQUEL(®)) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.Expression of hedgehog signal pathway in articular cartilage is associated with the severity of cartilage damage in rats with adjuvant-induced arthritis.A validated LC-MS/MS assay for simultaneous quantification of methotrexate and tofacitinib in rat plasma: application to a pharmacokinetic study.Development and validation of a RP-HPLC method for the quantitation of tofacitinib in rat plasma and its application to a pharmacokinetic study.The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension studyEfficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisSwitching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesPotential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patientsTofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trialTofacitinib.Extended-Release Once-Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate-Release Tofacitinib and Impact of Food.Evaluation of the Effect of Tofacitinib on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Volunteers.
P2860
Q26765028-987F6674-BD18-4917-8DA8-F270BE400A05Q26823326-D2C58730-FA1F-4EFB-98B1-CE679B0D2F66Q26852044-86B7D3B9-2760-47C9-A4EA-6A5A10488636Q27001957-5EBE895A-CB72-49D5-8FD1-BF154EB2083FQ27015831-CF66E75C-53EC-4819-9CED-AC622230FE60Q28552367-8D5323D6-C000-43A6-ABBD-415C48245F3BQ28674280-06BD51FD-D978-468D-A116-0B2B8F960DC8Q30313903-12E8F2A0-060C-46C8-947D-DEFF2A188BE6Q33578361-5E5581DE-42F3-42E5-AC20-3B5C5A80D7EAQ33703161-85112EA3-C185-43B2-8233-F2A3ED0D3EACQ33752141-F512E009-2669-4030-BEC2-FB7970622E69Q33775184-2F1F1F9D-80B1-4624-9211-6603DE042D58Q33837678-4457B12A-C3C5-41F1-9E0E-6AB6EE64268AQ34030650-74A6C6DB-3FEA-4FDC-893B-79230376B3B6Q34122846-AA9DA87B-AC5C-41A0-91BB-16E3EA736240Q34169114-0452A17D-6FB5-41F9-8E2E-52DA8F65EAA9Q34170436-4ECA8D6E-7326-4A53-96AA-32AA25A21229Q34275878-699D3B57-D5C3-4BBD-A37D-0B5FB07F16A0Q34276089-B278EBD8-2DCA-44BE-890A-6F5CCDD7677AQ34402215-5EDC1116-FD0E-4BD9-946B-8720EF45B94EQ34454531-E589D744-4DFE-44CA-B797-84AB2E50412CQ34851473-24B1CCC2-85BA-418E-A61D-B4E6718A98F7Q35226203-A9AC7702-D269-4B36-9C27-EDDE2A89E7D6Q35314876-ACE9490D-DA18-45A8-AD6F-FF7F5DF82C2BQ35549450-0C10EEDE-16FE-4E0E-AF60-AA5AFF57E5B1Q35605477-BDAE3303-F7C9-406F-8065-CAA628B10355Q35834909-383C6937-EBB4-4079-8D53-52CAF8ACEBB5Q36246592-F0F406EC-B704-48BE-953E-894BC75CC525Q36513512-EF332B1A-1BA7-4CE9-A9AD-90E5B8FC48EDQ36761766-91366714-3DC8-4BF6-8F32-1D9EB328F2BCQ36968737-294457FD-AAE9-4E88-AAFC-8A2C14F5E19AQ37031284-571EC530-8A11-42A7-8E74-AB46F16C8908Q37142451-6272A75C-DD5D-4ED4-9EE6-C330084822B1Q37148745-B1EF783E-FDE6-4C1A-95CE-E891D447507FQ37257476-ACCF7CA6-C9B4-4BC5-A6F8-0A4EC29BE830Q37311533-526AB6D1-EF01-4984-9233-92BBAE9F3B5DQ37312668-5D130710-AA96-4924-9276-BEA6959F06EAQ37340011-20CE526A-1854-465C-97B2-3ED3A3D0F9EAQ37420530-F264D259-5F39-421C-B9FE-5D41F6A9A858Q37461886-5E5815CA-9211-47D5-BFE5-1A7AFC19C9A3
P2860
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@ast
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@en
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@nl
type
label
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@ast
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@en
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@nl
prefLabel
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@ast
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@en
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@nl
P2093
P2860
P356
P1476
Anti-inflammatory activity and ...... at adjuvant-induced arthritis.
@en
P2093
Christie L Funckes-Shippy
Cindy J Gross
Dale L Morris
Debra M Meyer
James D Warner
Jeffrey L Hirsch
Jennifer L Barks
Martin E Dowty
Matthew J Saabye
Michael I Jesson
P2860
P2888
P356
10.1186/1476-9255-7-41
P577
2010-08-11T00:00:00Z
P5875
P6179
1023050699